Bone Biologics Inc (BBLG) Long-Term Liabilities to Equity

Historical price action serves as an indicator for Bone Biologics (BBLG), whose success depends on protein efficacy in bone regeneration and regulatory approvals. The brand's clinical authority among physicians due to NELL-1 prevails over shareholder confidence, and the metric stands at 0.00. The business relies on partnerships with specialized centers, collaborating with surgeons to create new approaches for treating severe skeletal injuries.

This indicator determines the proportion of long-term debt relative to the market value of equity. The calculation is based on a comparison of liabilities with a maturity exceeding one year and current market capitalization. The trend of the long-term debt-to-equity ratio reflects the evolution of the business's financial leverage. The low leverage of Bone Biologics (BBLG) confirms the stability of its financing structure. The absence of geopolitical risks in the US orthopedics sector further minimizes the company's dependence on external borrowed resources.